Brind.
  1. Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies.

Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.

2 reports, 2 independent Updated Sep 2
Gone quiet
Reports
2
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.

Who's involved

What this event is mainly about
FDAEli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.
  1. The FDA issued warnings regarding illegal semaglutide and tirzepatide, citing the smuggling of counterfeit Ozempic from China.Sub-event
  2. Eli Lilly's drug is being tested for market approval while also being advertised for illicit sales on TikTok in Brighton.Sub-event
  3. Black market drug sales of GLP-1 products are being intercepted by CBP.1 source

Keep exploring

Part of

Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped